Eli Lilly Launches Second Education Program for Medical Students - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eli Lilly Launches Second Education Program for Medical Students


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5
Eli Lilly and Company has developed its second medical student education program, an internship for future physicians. The Lilly Medical Student Intern Program, the second phase of its medical student programs, offers opportunities for medical students between their first and second years to work alongside healthcare professionals in the pharmaceutical industry to gain knowledge and experience in several areas, including preclinical research, clinical trial development, medical affairs, regulatory affairs, bio-ethics, and patient safety.

Six students from Marian University College of Osteopathic Medicine will be the first to participate in the intern program at Lilly’s Indianapolis headquarters. Students will expand their knowledge of the industry by spending time at other facilities, including Covance and Elanco, and participating in team-building activities with other summer interns across the company.

This is the second medical student program launched by Lilly this year. In February, Lilly announced a new partnership with Tulane University School of Medicine to launch the Medical Student Rotation Program, a four-week program for fourth-year medical students. The 10-week Lilly Medical Student Intern Program will run from May through August.

Source: Eli Lilly and Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here